Full-time Professors (Biomedicine)-Department of Life Sciences, NCU

•	EDUCATION & TRAINNING

2006~2010	B.S. Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan
2010~2011	M.S. graduate student Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan
2011~2014	Ph.D. Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan Ph.D. Dissertation: Synergistic Effect of Sorafenib Combines with Radiation or Vorinostat on Human Hepatocellular Carcinoma is via Inhibition of ERK/NF-B Signaling Pathway

•	CURRENT POSITIONS & RELEVANT EXPERIENCES

2021.08-present	Associate Professor Department of Biological Science and Technology China Medical University, Taichung, Taiwan
2019.08-present	Committee member Committee member of China Medical University Institutional Animal Care and Utilization Committee member of China Medical University Center of Environmental Protection and Safety and Health Committee member of Radiation Protection Committee member of Medical Research Core Facilities Center
2018.08-2021.07	Assistant Professor Department of Biological Science and Technology China Medical University, Taichung, Taiwan

2017.02-2018.07,

Assistant Professor Department of Radiology School of Medicine Taipei Medical University, Taipei, Taiwan

- Setup translation research lab (Wet bench)
- Establish NF-B molecular image platform for cancer related project
- Develop MR theranostic probe for cancer therapy, immune cells trafficking, stem cells tracing and diagnosis
- Optimize combination therapy of glioblastoma and hepatocellular carcinoma
- Validate treatment efficacy of potential compounds on cancer therapy (including new chemical compound,
Chinese herb and antidepressant drug)

2015.07-2018.07,	General Director Radiation Protection Committee Taipei Medical University Hospital, Taipei, Taiwan
2014.09-2018.07,	Medical Physicist Department of Medical Imaging Taipei Medical University Hospital, Taipei, Taiwan

- Establish radiation protection and dosage control project on Computer Tomography and Mammography
- Leading the research project on Mammography and dosage control
- Investigation of equipment performance, organization of quality control in imaging systems, design of radiation
installations, and control of radiation hazards
- Develop the applications of digital computer tomography in clinical
- Construct and organize the internship training program for students in Medical Physics, Medicine and
Radiological Technology

During the past nine years, I have been doing research in the field involving in cancer oncology,
molecular biology, radiobiology, molecular image, theranostic drugs application and cancer
immunology. This training process has helped me gain the skills in developing a specific imaging
biomarker using multi-modality of the molecular imaging (including Bioluminescence image, 7 T and
3T Magnetic resonance imaging techniques) in cancer detection and molecular tumor biology to
understand the tumor molecular mechanism. Our group is mainly working on therapeutic evaluation of
tumor oncology with various molecular image system supports. 1) We had successfully established
various molecular image monitoring systems on more than 8 types of cancer models, including
glioblastoma, non-small cell lung cancer, hepatocellular carcinoma, bladder cancer, colon cancer,
osteosarcoma…etc. 2) For oncology therapies development, we try to identify possible combination
treatment strategies, possible Chinese herb and also drug repurposing evaluation. 3) Importantly, we
constructed suitable mesenchymal stem cells tracking image system by MRI. This may effectively
support cell-based therapy to dynamically identify delivery and treatment efficacy. Cell-based therapy
system is a “Living Drugs” system, which display better potential to fight cancer. Fabricate MSCs
based gene delivery system may be used as a promising anti-tumor agent, which could provide a new
benefit for cancer patients. 4) Furthermore, we are also trying to establish theranostic probe platform
in oncology field by combination of target therapy drug, microRNA expression and MRI, which
will be helpful in comprehensive understanding and management of cancer. 5) Immune based
antibody therapy is another project of our group. We try to investigate various combination strategy of antibodies combination therapy on melanoma, colon rectal carcinoma and glioblastoma. Several patents
was also preparing according to our latest finding. Our researches are focus on comprehensively
encompass molecular images and therapeutic strategies to improve the cancer management. Thus, the
major GOAL of our research is the provision of new insights into oncology therapeutic approaches and
aimed at prolonging the overall patient survival.

1. Hsu FT*,#, Chen YZ*, Chin YC*, Chang LC*, Chiang SC, Yang LX, Liu HS, Yueh PF, Tu HL, He RU, Jeng LB, Shyu WC, Hu SH, Chiang IT, Liu YC, Chiu YC, Wu C, Yu CC, Su WP#, Huang CC# (2024) :  Harnessing the Power of Sugar-Based Nanoparticles: A Drug-Free Approach to Enhance Immune Checkpoint Inhibition against Glioblastoma and Pancreatic Cancer. ACS Nano doi: 10.1021/acsnano.4c07903. 
2. Yueh PF, Chiang CS, Tsai IJ, Yseng YL, Chen HR, Lan KL*, Hsu FT* (2024): A Multifunctional PEGylated Liposomal-Encapsulated Sunitinib Enhancing Autophagy, Immunomodulation, and Safety in Renal Cell Carcinoma. Journal of Nanobiotechnology 22(1):459. doi: 10.1186/s12951-024-02664-5.
3. Cheng HW, Lee W, Hsu FT, Lai YH, Huang SR, Lim SH, Lin ZK, Hsu SC, Chiang CS, Jeng LB, Shyu WC, Chen SY (2024): Manipulating the Crosstalk between Cancer and Immunosuppressive Cells with Phototherapeutic Gold-Nanohut for Reprogramming Tumor Microenvironment. Advanced Science 2024, 11, 2404347 doi: 10.1002/advs.202404347
4. Peng PH, Chen JL, Wu HH, Yang WH, Lin LJ, Lai CY, Chang JS, Syu JL, Wu HT, Hsu FT*, Cheng WC* and Hsu KW* (2023): Interplay between lncRNA RP11-367G18.1 variant 2 and YY1 plays a vital role in hypoxia-mediated gene expression and tumorigenesis. Cancer Cell International 23(1):266. doi: 10.1186/s12935-023-03067-6
5. Hsu FT, Liu WL, Lee SR, Jeng LB, Chen JH (2023): Unveiling nature’s potential weapon: Magnolol’s role in combating bladder cancer by upregulating the miR-124 and inactivating PKC-δ/ERK axis. Phytomedicine 119, 154947. doi: 10.1016/j.phymed.2023.154947
6. Yang CJ, Tan ZL, Yang JD, Hsu FT, Chiang CH (2023): Fluoxetine inactives STAT3/NF-κB signaling and promotes the sensitivity to cisplain in bladder cancer. Biomedicine & Pharmacotherapy 164:114962. doi: 10.1016/j.biopha.2023.114962
7. Huang HS, Lawal B, Chiang IT, Weng YS, Kuo YC, Liu YC, Hsu FT (2023): A Novel Isotope-labeled Small Molecule Probe CC12 for Anti-glioma via Suppressing LYN-mediated Progression and Activating Apoptosis Pathways. International Journal of Biological Sciences 19(10):3209-3225. doi: 10.7150/ijbs.82266.
8. Hsu LC, Ku HJ, Lin KH, Lee KC, Hsu FT (2023): Amentoflavone Induces Caspase-dependent/-independent Apoptosis and Dysregulate Cyclin-dependent Kinase Mediated Cell Cycle in Colorectal Cancer in vitro and in vivo. Environmental Toxicology 38(5):1078-1089. doi: 10.1002/tox.23749
9. \Weng YS, Chiang IT, Tsai JJ, Liu YC, Hsu FT (2023): Lenvatinib synergistically promotes radiotherapy on hepatocellular carcinoma via inhibiting Src/STAT3/NF-kappaB mediated epithelial-mesenchymal transition and metastasis. International Journal of Radiation Oncology, Biology, Physics S0360-3016(22)03352-1. doi: 10.1016/j.ijrobp.2022.09.060.
10. Chin YC, Yang LX, Hsu FT*, Hsu CW, Chang TW, Chen HY, Chen YC, Chia C, Hung CC*, Lao MY* (2022): Iron chlorophyll-guided Fe3O4 nano-assembly and adoption of an advanced ferroptosis strategy to enhance photodynamic immunotherapy on bladder cancer. Journal of Nanobiotechnology. 11;20(1):373. doi: 10.1186/s12951-022-01575-7.
11. Chiang IT, Liu YC, Liu HS, Ahmed Ali AA, Chou SY, Hsu TI, Hsu FT (2022): Regorafenib Reverses Temozolomide-induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. Neurotherapeutics 19(2):616-634. doi: 10.1007/s13311-022-01194-y.
12. Hsu FT*, Tsai CL*, Chiang IT*, Lan KH, Yueh PF, Liang WY, Lin CS, Chao Y, Lan KL (2022): The Synergistic Effect of Abraxane that Combines Human IL15 Fused with an Albumin-binding Domain on Murine Models of Pancreatic Ductal Adenocarcinoma. Journal of Cellular and Molecular Medicine 26(7):1955-1968. doi: 10.1111/jcmm.17220.
13. Chiang IT, Lee YH, Tan ZL, Hsu FT*, Tu HF* (2022): Regorafenib Enhances Antitumor Immune Efficacy of Anti-PD-L1 Immunotherapy on Oral Squamous Cell Carcinoma. Biomedicine & Pharmacotherapy 147:112661. doi: 10.1016/j.biopha.2022.112661
14. Wu CH*, Hsu FT*, Chao TL*, Lee YH, Kuo YC (2021): Revealing the Suppression Role of Protein Kinase C delta and the p38 Mitogen-activated Protein Kinase (MAPK)/NF-κB Axis Associated with Lenvatinib-inhibited Progression of Hepatocellular Carcinoma In Vitro and In Vivo. Biomedicine & Pharmacotherapy 145:112437
15. Hsu FT, Chiang IT, Wang WS (2020): Induction of Apoptosis Through Extrinsic/Intrinsic Pathways and Suppression of ERK/NF-B Signaling Participate in the Imipramine-inhibited Progression of Glioblastoma. Journal of Cellular and Molecular Medicine 24(7):3982–4000.

1. The selected novitiate student at Center for Functional Onco-imaging, University of California-Irvine,
Irvine, Orange County, California, USA, 2008
2. The outstanding poster award in 16th Taiwan Joint Cancer Conference, 2011
3. The scholarship award granted from National Yang-Ming University, 2011-2012
4. The selected oral speaker in World Molecular Imaging Congress, San Diego, USA, 2011
5. The selected student travel award in World Molecular Imaging Congress, San Diego, USA, 2011
6. The selected student travel award in World Molecular Imaging Congress, Dublin, Ireland, 2012
7. The first place poster award in Taiwan International Symposium for Molecular Imaging, 2012
8. The selected student travel award in World Molecular Imaging Congress, Savannah, USA, 2013
9. The outstanding speaker award in 9th Symposium of Medical Imaging and Radiological Sciences, 2013
10. Member of the Phi Tau Phi Scholastic Honor Society, 2014
11. The outstanding poster award in National Yang-Ming University Research Conference, 2014
12. The silver medal winner of Research Conference in Taipei Medical University Hospital, 2014 The
selected oral abstract in International Society for Magnetic Resonance in Medicine, Singapore, 2016
13. The selected young researcher travel award in International Society for Magnetic Resonance in
Medicine, Singapore, 2016
14. The selected oral abstract in International Society for Radiological Society of North America 2017
15. The excellent researcher support from MOST, 2017 (MOST 106-2924-I-038- 001-ESR)
16. The excellent researcher support from MOST, 2018 (MOST 107-2924-I-038-001-ESR)
17. The excellent researcher support from MOST, 2019 (MOST108-2821-C-039-001-ES)
18. The excellent teaching material award 2020, China Medical University (Biomedical imaging: principals
& applications)
19. The excellent researcher support from MOST, 2020 (MOST109-2821-C-039-001-ES)
20. The excellent researcher support from MOST, 2021 (MOST111-2821-C-039-001-ES)
21. The excellent assistant professor award (2017-2020), China Medical University (Top 2%).
22. 2021-18th National Intervention Award in the Business Category
23. The excellent associate professor award (2020-2023), China Medical University (Top 2%).

Polyethylene glycol (PEG)-coated Superparamagnetic iron oxide (SPIO) fabrication for cancer
therapeutic and diagnosis. Certification ID: I644687, Taiwan
2018.12.21 ~ 2036.11.29
Provisional application USA (C42803/US11476): Using miRNA-124 and PD-1 dual genes engineering
system on mesenchymal stem cell to develop cancer therapy platform

- Associate Professor Certificate, Ministry of Education, Reg. No: 148450, 2021, Taiwan.
- Assistant Professor Certificate, Ministry of Education, Reg. No: 144755, 2017, Taiwan.
- Certificate of Medical Radiation Technologist, Ministry of Health and Welfare, Reg. No: 006897, 2010,
Taiwan.
- Certificate of annual Computer tomography quality-assurance (CT QA)
- Certificate of annual Fluoroscopy quality-assurance (FL QA)
- Certificate of monthly Mammography quality-assurance (MA QA)
- Member of World Molecular Imaging Society, USA.
- Member of Radiological Society of North America, USA.
- Active member of American Association for Cancer Research, USA